Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value (NASDAQ:OCGN)
Kanizphoto/iStock via Getty Images Ocugen, Inc. (NASDAQ:OCGN) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being advanced in phase 1/2 studies for the treatment of patients with Geographic Atrophy [GA], and Stargardt Disease, respectively. Preliminary […]
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value (NASDAQ:OCGN) Read More »